Hero Matti, Wickman Sanna, Dunkel Leo
Hospital for Children and Adolescents, Helsinki University Central Hospital, Helsinki, Finland.
Clin Endocrinol (Oxf). 2006 May;64(5):510-3. doi: 10.1111/j.1365-2265.2006.02499.x.
We investigated whether inhibition of oestrogen biosynthesis with the aromatase inhibitor, letrozole, during adolescence improves near-final height in boys with constitutional delay of puberty.
Seventeen boys with constitutional delay of puberty were randomized to receive testosterone (T) enanthate (1 mg/kg i.m.) every 4 weeks for 6 months in combination with placebo (Pl, n = 8), or the aromatase inhibitor letrozole (Lz, 2.5 mg/day orally) (n = 9), for 12 months. After treatment, patients were followed up until near-final height. Height discrepancy was calculated as near-final height minus mid-parental target height.
The primary end point was the difference in near-final height between the groups treated either with T + Pl or T + Lz. Secondarily, height discrepancy and gain in height standard deviation score (SDS) were analysed in both groups.
Boys treated with T + Lz reached a higher mean near-final height than did boys on T + Pl (175.8 vs. 169.1 cm, respectively, P = 0.04). In T + Lz-treated boys, mean near-final height did not differ from their mid-parental target height (175.8 vs. 177.1 cm, P = 0.38), whereas in T + Pl-treated boys, mean near-final height was lower than mid-parental target height (169.1 vs. 173.9 cm, P = 0.007). T + Lz-treated boys had a greater increment in height SDS over the pretreatment height SDS than T + Pl-treated boys (+1.4 SDS vs.+0.8 SDS, P = 0.03).
Our findings indicate that in adolescent boys an increase in adult height can be attained by use of aromatase inhibitors.
我们研究了在青春期使用芳香化酶抑制剂来曲唑抑制雌激素生物合成是否能提高体质性青春期延迟男孩的最终身高。
17名体质性青春期延迟男孩被随机分为两组，一组每4周接受一次庚酸睾酮（1毫克/千克，肌肉注射），共6个月，并联合使用安慰剂（P1，n = 8）；另一组接受芳香化酶抑制剂来曲唑（Lz，2.5毫克/天，口服）（n = 9），共12个月。治疗后，对患者进行随访直至接近最终身高。身高差异计算为最终身高减去父母平均身高的目标身高。
主要终点是接受睾酮+安慰剂或睾酮+来曲唑治疗的两组之间最终身高的差异。其次，分析两组的身高差异和身高标准差得分（SDS）的增加情况。
接受睾酮+来曲唑治疗的男孩平均最终身高高于接受睾酮+安慰剂治疗的男孩（分别为175.8厘米和169.1厘米，P = 0.04）。在接受睾酮+来曲唑治疗的男孩中，平均最终身高与父母平均身高的目标身高无差异（175.8厘米对177.1厘米，P = 0.38），而在接受睾酮+安慰剂治疗的男孩中，平均最终身高低于父母平均身高的目标身高（169.1厘米对173.9厘米，P = 0.007）。接受睾酮+来曲唑治疗的男孩相比接受睾酮+安慰剂治疗的男孩，其身高SDS较治疗前的增加幅度更大（+1.4 SDS对+0.8 SDS，P = 0.03）。
我们的研究结果表明，对于青春期男孩，使用芳香化酶抑制剂可增加成年身高。
